Dr. Hrishikesh Satish Kulkarni, MD

Dr. Kulkarni practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Kulkarni's NPI, 1295050466, was assigned on March 31, 2010. Dr. Kulkarni graduated from Seth G.S. Medical College in 2009. Dr. Kulkarni holds California license C200195.

Dr. Kulkarni's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Kulkarni's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Kulkarni to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kulkarni practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Kulkarni's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Kulkarni is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kulkarni's licenses on file in 3 states: California, Missouri and Pennsylvania.

CMS data shows 86 Medicare services from Dr. Kulkarni across 2 procedure codes in 2024, for 87 Medicare patients. Medicare paid $9,139 for them.

CMS counts 87 Medicare patients who saw Dr. Kulkarni in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 3.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kulkarni's median patient age at 61, with 42% women.

In 2024, Dr. Kulkarni wrote 207 Medicare Part D claims for 37 patients. 87% of them were for generic drugs. CMS names the drug for 116 of them, across 6 drugs with 11 or more claims each, at $2,715 in total drug cost. In 2023, CMS named 130 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Kulkarni for performance year 2024, reported as part of a group. Dr. Kulkarni accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kulkarni as offering telehealth.

Dmand AI links 92 papers to Dr. Kulkarni, published from 2010 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Lung Transplantation, Lung and Complement Activation. Dr. Kulkarni has published most often in Am J Respir Cell Mol Biol. Dr. Kulkarni's most frequent co-authors are Daniel Kreisel, MD, Derek Ernest Byers, MD and Chad Alan Witt, MD.

CMS Open Payments shows 7 general payments to Dr. Kulkarni from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. CSL Behring paid the most, $1,472.

Dr. Kulkarni graduated from Seth G.S. Medical College in 2009. Dr. Kulkarni is a member of ACCP, ACP and ATS.

Dr. Kulkarni is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.